BR112023002533A2 - Formulações tópicas estáveis de 1(r)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol - Google Patents

Formulações tópicas estáveis de 1(r)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol

Info

Publication number
BR112023002533A2
BR112023002533A2 BR112023002533A BR112023002533A BR112023002533A2 BR 112023002533 A2 BR112023002533 A2 BR 112023002533A2 BR 112023002533 A BR112023002533 A BR 112023002533A BR 112023002533 A BR112023002533 A BR 112023002533A BR 112023002533 A2 BR112023002533 A2 BR 112023002533A2
Authority
BR
Brazil
Prior art keywords
topical formulations
oxaborolan
propoxyphenyl
pyridin
methoxy
Prior art date
Application number
BR112023002533A
Other languages
English (en)
Inventor
Yeow Yeoh Thean
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112023002533A2 publication Critical patent/BR112023002533A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÕES TÓPICAS ESTÁVEIS DE 1(R)-4-(5-(4-METÓXI-3-PROPOXIFENIL)PIRIDIN-3-IL)-1,2-OXABOROLAN-2-OL. A presente invenção refere-se à descoberta de formulações tópicas quimicamente e fisicamente estáveis compreendendo (R)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol (PF-07038124) para o tratamento de distúrbios inflamatórios e métodos de preparação das formulações tópicas.
BR112023002533A 2020-08-20 2021-08-16 Formulações tópicas estáveis de 1(r)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol BR112023002533A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068126P 2020-08-20 2020-08-20
US202163222126P 2021-07-15 2021-07-15
PCT/IB2021/057518 WO2022038485A1 (en) 2020-08-20 2021-08-16 Stable topical formulations of 1(r)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol

Publications (1)

Publication Number Publication Date
BR112023002533A2 true BR112023002533A2 (pt) 2023-03-14

Family

ID=77447970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002533A BR112023002533A2 (pt) 2020-08-20 2021-08-16 Formulações tópicas estáveis de 1(r)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol

Country Status (10)

Country Link
US (1) US20230310472A1 (pt)
EP (1) EP4199902A1 (pt)
JP (1) JP2023538362A (pt)
KR (1) KR20230069908A (pt)
CN (1) CN115916260A (pt)
BR (1) BR112023002533A2 (pt)
CA (1) CA3191886A1 (pt)
MX (1) MX2023002086A (pt)
TW (1) TWI787962B (pt)
WO (1) WO2022038485A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202404610A (zh) * 2022-06-24 2024-02-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的結晶、其製備方法及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
ES2858311T3 (es) * 2015-11-30 2021-09-30 Anacor Pharmaceuticals Inc Formulaciones farmacéuticas tópicas para el tratamiento de afecciones relacionadas con inflamación
KR102648015B1 (ko) * 2018-02-07 2024-03-14 시므라이즈 아게 화장품 조성물들의 안정화를 위한 [6]-파라돌 ([6]-paradol) 의 용법
CU20210023A7 (es) 2018-10-05 2021-10-12 Pfizer Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4

Also Published As

Publication number Publication date
WO2022038485A1 (en) 2022-02-24
MX2023002086A (es) 2023-03-15
KR20230069908A (ko) 2023-05-19
CN115916260A (zh) 2023-04-04
TW202216167A (zh) 2022-05-01
JP2023538362A (ja) 2023-09-07
CA3191886A1 (en) 2022-02-24
TWI787962B (zh) 2022-12-21
EP4199902A1 (en) 2023-06-28
US20230310472A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201992300A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 6-(ЦИКЛОПРОПАНКАРБОКСАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-N-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
MX2020001403A (es) Nuevos derivados de quinolina.
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
CY1124631T1 (el) 11-υποκατεστημενες 24-υδροξυστερολες για χρηση στην αγωγη nmda σχετιζομενων παθησεων
CY1126082T1 (el) Τροποποιητες toy trex1
CY1109333T1 (el) 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων
NO20060424L (no) 5-heteroringbaserte P38 kinaseinhibitorer
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
NO20084328L (no) Nye forbindelser
DK2150530T3 (da) Substituerede sulfonamid-derivater
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
MX2020011873A (es) Nuevos derivados de quinolina.
MX2020003594A (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd.
EP3860571A4 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
WO2022038365A3 (en) Fumarate derivatives and their medical use
BR112023002533A2 (pt) Formulações tópicas estáveis de 1(r)-4-(5-(4-metóxi-3-propoxifenil)piridin-3-il)-1,2-oxaborolan-2-ol
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
ATE331711T1 (de) Entzündungshemmende 3-arylthio-3- thiazolylalkylamine
BR112022020020A2 (pt) Métodos de tratamento da doença do coronavírus 2019

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing